$36.53
Price
$743M
Market Cap
—
P/E Ratio
-3.1
Forward P/E
$-9.83
EPS (TTM)
—
Dividend Yield
$270M
Cash
$103M
Total Debt
20M
Shares Out
$6.45
$66.92
52-Week Range
Institutional Ownership of NEKTAR THERAPEUTICS
|
Fund / Manager
Click to search
|
Shares | Value | % of Portfolio | Cost Basis | Est. Return |
|---|---|---|---|---|---|
| No funds currently hold this stock. | |||||
Trading Activity for NEKTAR THERAPEUTICS
|
Fund / Manager
Click to search
|
Action | Change | Shares After | Value | Price |
|---|---|---|---|---|---|
| No activity found for this stock. | |||||
Insider Trading for NEKTAR THERAPEUTICS
6 Months Insider Sentiment
Buy $0
Sell $0
0
Buys
0
Sells
+0
Net
2
Grants
| Date |
Insider
Click to search
|
Role
Click to search
|
Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Dec 22, 2025 | Howard W Robin | President & CEO | GRANT | 21.7K | — | — |
| Dec 22, 2025 | Jonathan Zalevsky | Chief R&D Officer | GRANT | 6.2K | — | — |